Literature DB >> 21173164

Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2.

Hui Zheng1, Juan Qian, Bentley Varghese, Darren P Baker, Serge Fuchs.   

Abstract

Alpha interferon (IFN-α) controls homeostasis of hematopoietic stem cells, regulates antiviral resistance, inhibits angiogenesis, and suppresses tumor growth. This cytokine is often used to treat cancers and chronic viral infections. The extent of cellular responses to IFN-α is limited by the IFN-induced ubiquitination and degradation of the IFN-α/β receptor chain 1 (IFNAR1) chain of the cognate receptor. IFNAR1 ubiquitination is facilitated by the βTrcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand. Here we report identification of protein kinase D2 (PKD2) as a kinase that mediates the ligand-inducible phosphorylation of IFNAR1 degron and enables binding of βTrcp to the receptor. Treatment of cells with IFN-α induces catalytic activity of PKD2 and stimulates its interaction with IFNAR1. Expression and kinase activity of PKD2 are required for the ligand-inducible stimulation of IFNAR1 ubiquitination and endocytosis and for accelerated proteolytic turnover of IFNAR1. Furthermore, inhibition or knockdown of PKD2 robustly augments intracellular signaling induced by IFN-α and increases the efficacy of its antiviral effects. The mechanisms of the ligand-inducible elimination of IFNAR1 are discussed, along with the potential medical significance of this regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173164      PMCID: PMC3028644          DOI: 10.1128/MCB.01154-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

Review 1.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  Negative regulation of type I interferon signaling: facts and mechanisms.

Authors:  E M Coccia; G Uzé; S Pellegrini
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2006-05-15       Impact factor: 1.770

Review 4.  Negative receptor signalling.

Authors:  Ivan Dikic; Silvia Giordano
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

5.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

6.  Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling.

Authors:  S P Sidorenko; C L Law; S J Klaus; K A Chandran; M Takata; T Kurosaki; E A Clark
Journal:  Immunity       Date:  1996-10       Impact factor: 31.745

7.  Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor.

Authors:  V S Spiegelman; T J Slaga; M Pagano; T Minamoto; Z Ronai; S Y Fuchs
Journal:  Mol Cell       Date:  2000-05       Impact factor: 17.970

8.  Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network.

Authors:  Charles Yeaman; M Inmaculada Ayala; Jessica R Wright; Frederic Bard; Carine Bossard; Agnes Ang; Yusuke Maeda; Thomas Seufferlein; Ira Mellman; W James Nelson; Vivek Malhotra
Journal:  Nat Cell Biol       Date:  2004-01-25       Impact factor: 28.824

9.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

10.  Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis.

Authors:  K G Suresh Kumar; Hervé Barriere; Christopher J Carbone; Jianghuai Liu; Gayathri Swaminathan; Ping Xu; Ying Li; Darren P Baker; Junmin Peng; Gergely L Lukacs; Serge Y Fuchs
Journal:  J Cell Biol       Date:  2007-12-03       Impact factor: 10.539

View more
  50 in total

1.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Authors:  Hui Zheng; Juan Qian; Christopher J Carbone; N Adrian Leu; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

2.  Type I Interferons Control Proliferation and Function of the Intestinal Epithelium.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Audrey Lasri; Ning Li; Daniel P Beiting; Amy C Durham; Ting Yang; Eli Pikarsky; Christopher J Lengner; F Brad Johnson; Yinon Ben-Neriah; Serge Y Fuchs
Journal:  Mol Cell Biol       Date:  2016-01-25       Impact factor: 4.272

3.  CCR2 Signaling Selectively Regulates IFN-α: Role of β-Arrestin 2 in IFNAR1 Internalization.

Authors:  Dionna W Williams; Lauren C Askew; Elonna Jones; Janice E Clements
Journal:  J Immunol       Date:  2018-11-30       Impact factor: 5.422

Review 4.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

5.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

6.  Type 1 interferons contribute to the clearance of senescent cell.

Authors:  Yuliya V Katlinskaya; Christopher J Carbone; Qiujing Yu; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

7.  Ubiquitin-dependent Turnover of Adenosine Deaminase Acting on RNA 1 (ADAR1) Is Required for Efficient Antiviral Activity of Type I Interferon.

Authors:  Lemin Li; Guanghui Qian; Yibo Zuo; Yukang Yuan; Qiao Cheng; Tingting Guo; Jin Liu; Chang Liu; Liting Zhang; Hui Zheng
Journal:  J Biol Chem       Date:  2016-10-11       Impact factor: 5.157

8.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

Review 9.  Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.

Authors:  Jacob Piehler; Christoph Thomas; K Christopher Garcia; Gideon Schreiber
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.